Austin Health

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1882-01-01

Employees: 5K

Market Cap: -

Website: https://www.austin.org.au

Clinical Trials

The ElectRx Study - A Neurotechnology Approach to the Treatment of IBD

Not Applicable

Recruiting

Conditions: Crohn Disease

First Posted Date: 2022-07-22

Last Posted Date: 2023-02-08

Lead Sponsor: Austin Health

Target Recruit Count: 13

Registration Number: NCT05469607

Locations: 🇦🇺
Austin Health, Melbourne, Victoria, Australia

The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge

Not Applicable

Completed

Conditions: Hypersensitivity, Immediate
Hypersensitivity, Delayed
Hypersensitivity Response

Interventions: Other: Standard of care
Other: Direct oral penicillin challenge

First Posted Date: 2020-07-01

Last Posted Date: 2023-03-06

Lead Sponsor: Austin Health

Target Recruit Count: 382

Registration Number: NCT04454229

Locations: 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 3 locations

Endoscopy-related Phone Consultation During the COVID-19 Outbreak

Completed

Conditions: Colon Disease
Colon Polyp
Reflux, Gastroesophageal
Varices, Esophageal

Interventions: Other: None - NA

First Posted Date: 2020-04-14

Last Posted Date: 2020-07-09

Lead Sponsor: Austin Health

Target Recruit Count: 186

Registration Number: NCT04344964

Locations: 🇦🇺
Austin Health, Melbourne, Victoria, Australia

A Trial of Radiotherapy and Durvalumab in DLBCL and FL

Phase 1

Completed

Conditions: Follicular Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: Durvalumab
Radiation: Radiotherapy
Radiation: Radiotherapy (cohort 6 only)

First Posted Date: 2018-08-01

Last Posted Date: 2024-04-12

Lead Sponsor: Austin Health

Target Recruit Count: 34

Registration Number: NCT03610061

Locations: 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺
Monash Health, Clayton, Victoria, Australia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

Early Phase 1

Active, not recruiting

Conditions: Lymphomas Non-Hodgkin's B-Cell

Interventions: Drug: Avelumab

First Posted Date: 2017-08-09

Last Posted Date: 2024-07-30

Lead Sponsor: Austin Health

Target Recruit Count: 28

Registration Number: NCT03244176

Locations: 🇦🇺
Ballarat Health, Ballarat, Victoria, Australia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺
Eastern Health, Box Hill, Victoria, Australia

Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis

Phase 4

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Infliximab

First Posted Date: 2016-05-12

Last Posted Date: 2024-10-08

Lead Sponsor: Austin Health

Target Recruit Count: 138

Registration Number: NCT02770040

Locations: 🇦🇺
Austin Health, Melbourne, Victoria, Australia

An Assessment of the Feasibility and Safety of Conservative Oxygen Therapy in Critically Ill Patients

Phase 1

Completed

Conditions: Critical Illness

Interventions: Other: conservative O2 therapy
Other: standard care

First Posted Date: 2012-09-12

Last Posted Date: 2013-07-11

Lead Sponsor: Austin Health

Target Recruit Count: 105

Registration Number: NCT01684124

Locations: 🇦🇺
Austin Hospital, Melbourne, Victoria, Australia

An Assessment of Pulse Pressure Variation to Guide Fluid Therapy in Cardiac Surgery Patients

Phase 2

Completed

Conditions: Cardiac Surgery

Interventions: Other: IV fluid according to PPV
Other: fluids according to standard care

First Posted Date: 2012-09-10

Last Posted Date: 2013-07-11

Lead Sponsor: Austin Health

Target Recruit Count: 104

Registration Number: NCT01681758

Locations: 🇦🇺
Austin Hospital, Melbourne, Victoria, Australia

Testosterone and Weight Loss

Phase 2

Completed

Conditions: Obesity in Men

Interventions: Drug: placebo
Drug: Testosterone

First Posted Date: 2012-06-12

Last Posted Date: 2016-06-06

Lead Sponsor: Austin Health

Target Recruit Count: 100

Registration Number: NCT01616732

Locations: 🇦🇺
Austin Health, Heidelberg, Victoria, Australia

Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer

Phase 2

Conditions: Metastatic Colorectal Cancer

First Posted Date: 2010-11-30

Last Posted Date: 2010-11-30

Lead Sponsor: Austin Health

Target Recruit Count: 40

Registration Number: NCT01249521

Locations: 🇦🇺
Austin Health, Melbourne, Victoria, Australia

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy